Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CADILA HEALTHCARE Mar-20 |
MYLAN Dec-18 |
CADILA HEALTHCARE/ MYLAN |
5-Yr Chart Click to enlarge
|
||
High | Rs | 352 | 3,474 | - | |
Low | Rs | 207 | 1,912 | - | |
Sales per share (Unadj.) | Rs | 139.2 | 1,598.5 | - | |
Earnings per share (Unadj.) | Rs | 11.8 | 43.4 | - | |
Cash flow per share (Unadj.) | Rs | 18.6 | 342.7 | - | |
Dividends per share (Unadj.) | Rs | 3.50 | 0 | - | |
Dividend yield (eoy) | % | 1.3 | 0 | - | |
Book value per share (Unadj.) | Rs | 101.4 | 1,729.3 | - | |
Shares outstanding (eoy) | m | 1,023.74 | 514.50 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 2.0 | 1.7 | 119.1% | |
Avg P/E ratio | x | 23.7 | 62.0 | 38.3% | |
P/CF ratio (eoy) | x | 15.0 | 7.9 | 191.5% | |
Price / Book Value ratio | x | 2.8 | 1.6 | 177.0% | |
Dividend payout | % | 29.8 | 0 | - | |
Avg Mkt Cap | Rs m | 286,033 | 1,385,529 | 20.6% | |
No. of employees | `000 | 13.4 | 35.0 | 38.3% | |
Total wages/salary | Rs m | 24,145 | 0 | - | |
Avg. sales/employee | Rs Th | 10,632.7 | 23,497.5 | 45.3% | |
Avg. wages/employee | Rs Th | 1,801.2 | 0 | - | |
Avg. net profit/employee | Rs Th | 898.5 | 638.1 | 140.8% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 142,531 | 822,412 | 17.3% | |
Other income | Rs m | 1,139 | 0 | - | |
Total revenues | Rs m | 143,670 | 822,412 | 17.5% | |
Gross profit | Rs m | 24,198 | 212,810 | 11.4% | |
Depreciation | Rs m | 6,965 | 153,988 | 4.5% | |
Interest | Rs m | 3,418 | 39,555 | 8.6% | |
Profit before tax | Rs m | 14,954 | 19,267 | 77.6% | |
Minority Interest | Rs m | 288 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 3,198 | -3,065 | -104.3% | |
Profit after tax | Rs m | 12,044 | 22,332 | 53.9% | |
Gross profit margin | % | 17.0 | 25.9 | 65.6% | |
Effective tax rate | % | 21.4 | -15.9 | -134.4% | |
Net profit margin | % | 8.5 | 2.7 | 311.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 87,154 | 459,234 | 19.0% | |
Current liabilities | Rs m | 82,694 | 334,832 | 24.7% | |
Net working cap to sales | % | 3.1 | 15.1 | 20.7% | |
Current ratio | x | 1.1 | 1.4 | 76.8% | |
Inventory Days | Days | 71 | 84 | 85.5% | |
Debtors Days | Days | 94 | 93 | 100.5% | |
Net fixed assets | Rs m | 133,236 | 159,534 | 83.5% | |
Share capital | Rs m | 1,024 | 438 | 233.9% | |
Net worth | Rs m | 103,757 | 889,699 | 11.7% | |
Long term debt | Rs m | 32,146 | 960,271 | 3.3% | |
Total assets | Rs m | 236,866 | 2,386,519 | 9.9% | |
Interest coverage | x | 5.4 | 1.5 | 361.5% | |
Debt to equity ratio | x | 0.3 | 1.1 | 28.7% | |
Sales to assets ratio | x | 0.6 | 0.3 | 174.6% | |
Return on assets | % | 6.5 | 2.6 | 251.7% | |
Return on equity | % | 11.6 | 2.5 | 462.5% | |
Return on capital | % | 13.7 | 3.2 | 431.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 25,054 | 170,897 | 14.7% | |
From Investments | Rs m | -10,123 | -88,335 | 11.5% | |
From Financial Activity | Rs m | -10,942 | -79,614 | 13.7% | |
Net Cashflow | Rs m | 3,989 | 1,416 | 281.7% |
Compare CADILA HEALTHCARE With: ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Compare CADILA HEALTHCARE With: ALEMBIC PHARMA UNICHEM LAB STRIDES PHARMA SCIENCE AJANTA PHARMA DISHMAN PHARMA
Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.
Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.
For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
More Views on NewsIn this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.
Our ace stock picker is ready to capitalise on a big growth opportunity.
More